In vivo fate of lipid-based nanoparticles

被引：67
|
作者：
Qi, Jianping [1 ]
Zhuang, Jie [2 ]
Lu, Yi [1 ]
Dong, Xiaochun [1 ]
Zhao, Weili [1 ,3 ]
Wu, Wei [1 ]
机构：
[1] Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery MOE & PLA, Shanghai, Peoples R China
[2] Shanghai Univ Med & Hlth Sci, Sch Pharm, Shanghai, Peoples R China
[3] Henan Univ, Key Lab Special Funct Mat, Minist Educ, Kaifeng, Peoples R China
来源：
DRUG DISCOVERY TODAY | 2017年 / 22卷 / 01期
基金：
中国国家自然科学基金;
关键词：
ORAL BIOAVAILABILITY; DELIVERY-SYSTEM; SIRNA DELIVERY; DRUG-DELIVERY; PARTICLE-SIZE; CHAIN-LENGTH; CARRIERS NLC; BIODISTRIBUTION; ABSORPTION; FORMULATIONS;
D O I：
10.1016/j.drudis.2016.09.024
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The in vivo fate of lipid-based nanoparticles (LBNs) is essentially determined by the properties of their lipid compositions. LBNs are rapidly degraded via lipolysis wherever lipases are abundant, especially in the gastrointestinal tract. LBNs that survive lipolysis can be translocated through the circulation to reach terminal organs or tissues. Lipid composition, particle size, and surface decoration, as well as the formation of protein corona, are the main factors influencing the in vivo fate of LBNs. As we discuss here, elucidation of the in vivo fate of LBNs helps weigh the balance between lipolysis and biorecognition, and is emerging as a new field of research.
引用
收藏
页码：166 / 172
页数：7
相关论文
共 50 条
  • [1] In Vivo Delivery of RNAi with Lipid-Based Nanoparticles
    Huang, Leaf
    Liu, Yang
    [J]. ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 13, 2011, 13 : 507 - 530
  • [2] Biological fate of ingested lipid-based nanoparticles: current understanding and future directions
    Wang, Taoran
    Luo, Yangchao
    [J]. NANOSCALE, 2019, 11 (23) : 11048 - 11063
  • [3] Surface Modification of Lipid-Based Nanoparticles
    Xu, Yining
    Fourniols, Thibaut
    Labrak, Yasmine
    Preat, Veronique
    Beloqui, Ana
    des Rieux, Anne
    [J]. ACS NANO, 2022, 16 (05) : 7168 - 7196
  • [4] Lipid-based nanoparticles for treatment of cancer
    Sheoran, Sumit
    Arora, Swati
    Samsonraj, R.
    Govindaiah, Pilli
    Vuree, Sugunakar
    [J]. HELIYON, 2022, 8 (05)
  • [5] Interactions of Apolipoproteins with Lipid-Based Nanoparticles
    Dalhaimer, Paul
    Florey, Brice
    Isaac, Sami
    [J]. ACS NANO, 2023, 17 (02) : 837 - 842
  • [6] Structural and componential design: new strategies regulating the behavior of lipid-based nanoparticles in vivo
    Zhong, Qingguo
    Zheng, Chunxiong
    Yi, Ke
    Mintz, Rachel L. L.
    Lv, Shixian
    Tao, Yu
    Li, Mingqiang
    [J]. BIOMATERIALS SCIENCE, 2023, 11 (14) : 4774 - 4788
  • [7] Effective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate
    Chakraborty, Subhashis
    Shukla, Dali
    Vuddanda, Parameswara Rao
    Mishra, Brahmeshwar
    Singh, Sanjay
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (06) : 774 - 779
  • [8] Lipid-Based Nanoparticles in Cardiovascular Molecular Imaging
    Geninatti Crich S.
    Alberti D.
    Orio L.
    Stefania R.
    Longo D.
    Aime S.
    [J]. Current Cardiovascular Imaging Reports, 2013, 6 (1) : 69 - 75
  • [9] Lipid-based nanoparticles for nucleic acid delivery
    Li, Weijun
    Szoka, Francis C., Jr.
    [J]. PHARMACEUTICAL RESEARCH, 2007, 24 (03) : 438 - 449
  • [10] Lipid-based Nanoparticles for Nucleic Acid Delivery
    Weijun Li
    Francis C. Szoka
    [J]. Pharmaceutical Research, 2007, 24 : 438 - 449
12345